Lincoln [LINCOLN] vs Jagsonpal [JAGSNPHARM] Detailed Stock Comparison

Lincoln

NSE
Loading...

Jagsonpal

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Lincoln wins in 10 metrics, Jagsonpal wins in 10 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

MetricLincolnJagsonpalBetter
P/E Ratio (TTM)12.9526.58Lincoln
Price-to-Book Ratio1.676.73Lincoln
Debt-to-Equity Ratio0.003.85Lincoln
PEG Ratio0.770.25Jagsonpal
EV/EBITDA8.9726.98Lincoln
Profit Margin (TTM)13.71%21.50%Jagsonpal
Operating Margin (TTM)13.19%15.69%Jagsonpal
EBITDA Margin (TTM)13.19%15.69%Jagsonpal
Return on Equity12.26%23.07%Jagsonpal
Return on Assets (TTM)10.33%19.90%Jagsonpal
Free Cash Flow (TTM)$737.71M$549.52MLincoln
Dividend Yield0.31%0.36%Jagsonpal
1-Year Return-26.92%46.11%Jagsonpal
Price-to-Sales Ratio (TTM)1.785.66Lincoln
Enterprise Value$9.23B$15.02BJagsonpal
EV/Revenue Ratio1.475.31Lincoln
Gross Profit Margin (TTM)54.96%64.39%Jagsonpal
Revenue per Share (TTM)$315$42Lincoln
Earnings per Share (Diluted)$43.13$9.04Lincoln
Beta (Stock Volatility)0.190.23Lincoln
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Lincoln vs Jagsonpal Stock Performance Analysis

Loading Price Chart...

Lincoln
Jagsonpal
Lincoln Stock Overview | Jagsonpal Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Lincoln-1.49%3.09%-0.39%-3.20%2.89%-34.64%
Jagsonpal-1.14%0.22%-5.95%3.84%12.88%-7.51%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Lincoln-26.92%92.23%115.24%160.29%160.29%160.29%
Jagsonpal46.11%55.59%1,326.59%1,978.88%2,263.49%951.37%

News Based Sentiment: Lincoln vs Jagsonpal

Lincoln

News based Sentiment: MIXED

The month presented a mixed picture for Lincoln Pharmaceuticals, with positive institutional investment countered by declining profitability and a cautious analyst rating. While the dividend and new R&D leadership are positive developments, the overall investment story is currently balanced between potential and risk.

View Lincoln News Sentiment Analysis

Jagsonpal

News based Sentiment: POSITIVE

Jagsonpal Pharmaceuticals reported impressive Q1 FY26 results with significant revenue and profit growth, and set ambitious targets for the future. While a customs penalty exists, the company is actively addressing it. These factors combine to create a generally positive outlook for the company.

View Jagsonpal News Sentiment Analysis

Performance & Financial Health Analysis: Lincoln vs Jagsonpal

MetricLINCOLNJAGSNPHARM
Market Information
Market Cap i₹11.21B₹16.77B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i26,423116,938
90 Day Avg. Volume i218,693525,668
Last Close₹551.80₹237.53
52 Week Range₹499.00 - ₹979.50₹153.10 - ₹328.04
% from 52W High-43.67%-27.59%
All-Time High₹979.50 (Dec 09, 2024)₹328.04 (Nov 25, 2024)
% from All-Time High-43.67%-27.59%
Growth Metrics
Quarterly Revenue Growth0.05%0.23%
Quarterly Earnings Growth0.17%1.03%
Financial Health
Profit Margin (TTM) i0.14%0.22%
Operating Margin (TTM) i0.13%0.16%
Return on Equity (TTM) i0.12%0.23%
Debt to Equity (MRQ) i0.003.85
Cash & Liquidity
Book Value per Share (MRQ)₹335.40₹35.72
Cash per Share (MRQ)₹97.95₹19.08
Operating Cash Flow (TTM) i₹967.87M₹532.93M
Levered Free Cash Flow (TTM) i₹823.46M₹553.61M
Dividends
Last 12-Month Dividend Yield i0.31%0.36%
Last 12-Month Dividend i₹1.80₹0.80

Valuation & Enterprise Metrics Analysis: Lincoln vs Jagsonpal

MetricLINCOLNJAGSNPHARM
Price Ratios
P/E Ratio (TTM) i12.9526.58
Forward P/E iN/AN/A
PEG Ratio i0.770.25
Price to Sales (TTM) i1.785.66
Price to Book (MRQ) i1.676.73
Market Capitalization
Market Capitalization i₹11.21B₹16.77B
Enterprise Value i₹9.23B₹15.02B
Enterprise Value Metrics
Enterprise to Revenue i1.475.31
Enterprise to EBITDA i8.9726.98
Risk & Other Metrics
Beta i0.190.23
Book Value per Share (MRQ) i₹335.40₹35.72

Financial Statements Comparison: Lincoln vs Jagsonpal

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)LINCOLNJAGSNPHARM
Revenue/Sales i₹1.68B₹756.12M
Cost of Goods Sold i₹801.52M₹269.27M
Gross Profit i₹880.31M₹486.85M
Research & Development iN/AN/A
Operating Income (EBIT) i₹234.93M₹118.60M
EBITDA i₹198.39M₹170.38M
Pre-Tax Income i₹162.47M₹144.31M
Income Tax i₹46.72M₹36.36M
Net Income (Profit) i₹115.75M₹107.95M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)LINCOLNJAGSNPHARM
Cash & Equivalents i₹134.14M₹112.15M
Total Current Assets i₹5.00B₹1.61B
Total Current Liabilities i₹1.06B₹259.04M
Long-Term Debt iN/A₹76.32M
Total Shareholders Equity i₹6.72B₹2.40B
Retained Earnings iN/AN/A
Property, Plant & Equipment i₹1.82B₹88.37M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)LINCOLNJAGSNPHARM
Operating Cash Flow iN/AN/A
Capital Expenditures iN/AN/A
Free Cash Flow iN/AN/A
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricLINCOLNJAGSNPHARM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Average Daily Volume (10 Day) i26,423116,938
Average Daily Volume (90 Day) i218,693525,668
Shares Outstanding i20.03M66.40M
Float Shares i8.79M16.17M
% Held by Insiders i0.55%0.76%
% Held by Institutions i0.01%0.03%

Dividend Analysis & Yield Comparison: Lincoln vs Jagsonpal

MetricLINCOLNJAGSNPHARM
Last 12-Month Dividend i₹1.80₹0.80
Last 12-Month Dividend Yield i0.31%0.36%
3-Year Avg Annual Dividend i₹1.60₹0.27
3-Year Avg Dividend Yield i0.35%0.49%
3-Year Total Dividends i₹4.80₹0.80
Ex-Dividend DateSep 13, 2024Sep 06, 2024